About Freenome Health
Freenome Health is a publicly listed company based in United States founded in 2014 by Gabriel Otte, Charles Roberts, and Riley Ennis. Provider of a deep learning platform for detecting circulating cancer-related markers. Freenome Health has raised $1.35 billion across 8 funding rounds from investors including Fidelity Investments, Verily and Kaiser Permanente. The company has 411 employees. Freenome Health has completed 1 acquisition, including Oncimmune. Freenome Health was last valued at $1.1 billion in July 2026. Its website freenome.com draws about 19 thousand monthly visits. Freenome Health offers products and services including Intelligent Screening Platform and Early Cancer Detection Tests. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Gastrointestinal Cancer. Its legal entity is Freenome Holdings, Inc. Its competitors include Miroculus, Geneoscopy and InterVenn; 3 of its 3 listed competitors have raised funding.
Company details
Freenome Health was founded in 2014 in the United States. A deep learning platform is offered for identifying circulating cancer-related markers in patient blood samples. Proprietary technology is utilized to detect cell-free DNA, immune cell fragments, and metabolic markers. Tumor types are classified through the platform, and treatment therapies for prostate, breast, colorectal, and lung cancers are supported in the health technology sector.
- Headquarters United States
- Employees 411
- Founders Gabriel Otte, Charles Roberts, Riley Ennis
- Stage Public
- SectorsHealthcare
- Website category Computers Electronics and Technology · Web Hosting and Domain Names
- Email••••••••
- Phone•••• ••••
- Website freenome.com
- Social LinkedIn X Facebook
- Legal Name Freenome, Inc.
- Total Equity Funding$1.35B (USD)
in 8 rounds
- Latest Funding Round$254M (USD), Series E
Feb 2024
- InvestorsFidelity Investments
& 64 more
- Employee Count411
- Investments & Acquisitions
Products & Services of Freenome Health
Freenome Health offers a comprehensive portfolio of products and services, including Intelligent Screening Platform and Early Cancer Detection Tests.
Uses AI and multiomics for early cancer detection via blood draws.
Develops and validates tests for treatable cancer stages.
Funding Insights of Freenome Health
Freenome Health has successfully raised a total of $1.35B across 8 strategic funding rounds. The most recent funding activity was a Series E round of $254 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.35B
- Total Rounds 8
- Last Round Series E — $254M
- First Round $700,000
(Jan 2014)
- Investors Count 65
All 8 funding rounds of Freenome Health with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | $254M | Series E | – | Roche | |
| Jan 2022 | $290M | Series D | – | Roche | |
| Nov 2021 | $300M | Series D | – | Perceptive Advisors, RA Capital Management | |
| Aug 2020 | $270M | Series C | – | Bain Capital, Perceptive Advisors | |
| Jun 2019 | $160M | Series B | – | RA Capital Management, Polaris Partners | |
| Feb 2017 | $72M | Series A | – | a16z, S32 | |
| May 2016 | $5.55M | Seed | – | a16z | |
| Jan 2014 | $700,000 | Grant | – | – | – |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of Freenome Health
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $1.1B (Jul 2026). 65 investors in total: 64 institutional and 1 angel.
Investors in Freenome Health
Freenome Health has secured backing from 65 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Fidelity Investments, Verily and Kaiser Permanente.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
BrightEdge is focused on impact investment in cancer care innovation. | brightedgefund.org | |||
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | a16z.com | |||
Venture capital firm investing in the healthcare sector | intermountainventures.com | Salt Lake City, United States | ||
Eventide is engaged in values-based investment management services. | 2008 | eventideinvestments.com | Boston, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Investment management services are provided focusing on healthcare innovation. | puravidainvestments.com | New York, United States | ||
Venture capital firm focused on multiple sectors | dcvc.com | Palo Alto, United States | ||
Tech startups are funded by S32, a venture capital entity. | s32.com | Sunnyvale, United States | ||
Early-stage startups are invested in by Artis Ventures. | av.co | San Francisco, United States |
Investor details for Freenome Health
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Freenome Health
119 people are tracked at Freenome Health (37 in leadership, 8 in board & advisors, 74 in team); the tracked headcount is 411.
| Name | Role | Group |
|---|---|---|
Gabriel Otte | Founder | Leadership |
Charles Roberts | Co-Founder | Leadership |
Riley Ennis | Co-Founder & CPO | Leadership |
Mike Nolan | CEO | Leadership |
Jimmy Lin | Chief Scientific Officer | Leadership |
Clinton Wu | VP, Finance | Leadership |
Chuck Ackerman | Director, Market Development | Leadership |
Marian Navratil | Vp, Development | Leadership |
Urvee Desai | Director Of Protein Development | Leadership |
Julie Tran | Chief People Officer | Leadership |
Victor Chubukov | Director, Computational Biology | Leadership |
Aric Ledford | Sr. Director, Intellectual Property | Leadership |
Victoria R. | VP Corporate Development | Leadership |
Sedide Ozturk | Director Of Corporate Development | Leadership |
Ofer Shapira | Director, Computational Biology | Leadership |
Linda McAllister M.D. | VP Clinical Development | Leadership |
Jojo Bui | Director, Quality Systems | Leadership |
Don Rackham | Senior Director, Quality | Leadership |
Daiana Kozak | Director, People Operations, Process & Analytics | Leadership |
Brian Gallo | Director, HR Business Partner | Leadership |
99 more people are available in the full profile.
Complete people profiles for Freenome Health
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Freenome Health
Freenome Health is a publicly listed company on the NASDAQ with ticker symbol FRNM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onNASDAQ: FRNM
- Listed entityFreenome, Inc.
- Exchange sectorHealth technology
- ISINUS35661P1003
- Share price$12.64 (-4.39% on the day) · 2026-10-13
- Market capitalisation$1.36B
- EPS (diluted, trailing year)$-0.07
- Volume (last session)840,560
Investments & Acquisitions by Freenome Health
Freenome Health has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Oncimmune.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Diagnostics and risk assessment solutions for lung cancer are developed. | oncimmune.com | Nottingham, United Kingdom | 2006 | May 2023 | •••• |
Complete acquisition details for Freenome Health
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Freenome Health
5 dated milestones of Freenome Health across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Freenome Health is founded.
- Funding First funding round of $700K.
- Milestone Reaches Unicorn status.
- Acquisition Acquires Oncimmune.
- Funding Latest funding round, Series E, of $254.0M.
Competitors of Freenome Health
Freenome Health has 3 listed competitors in our database, 3 of them funded. They include Miroculus, Geneoscopy and InterVenn.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| miroculus.com | 2014 | San Francisco, United States | $48.42M | MicroRNA profiling platform is developed to detect genes in samples. | ||
| geneoscopy.com | 2015 | St. Louis, United States | $218.95M | Non-invasive biomarker tests for colorectal cancer are developed. | ||
| intervenn.com | 2017 | San Francisco, United States | $250.9M | Provider of an AI-based clinical decision supporting tool for cancer detection and drug development |
Detailed competitors of Freenome Health
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Freenome Health
The website of Freenome Health (freenome.com) receives about 19.3K visits a month and ranks #1,036,615 among all websites worldwide, #3,158 in Web Hosting and Domain Names.
- Monthly visits19.3K
▼ 22.5% vs previous month
- Unique visitors13.7K
per month
- Global rank#1,036,615
among all websites
- Category rank#3,158
Computers Electronics and Technology · Web Hosting and Domain Names
- Bounce rate45%
- Pages per visit2.2
- Average visit1 min 37 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with Freenome Health. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| freenom.com | 100% | 339K | #124,843 | View details | |
| linkedin.com | 81% | 1.9B | #18 | View details | |
| google.com | 78% | 85.8B | #1 | View details | |
| reddit.com | 76% | 4.4B | #9 | View details | |
| x.com | 63% | 4.5B | #5 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Freenome Health
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Freenome Health (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Freenome Health
Complete news archive for Freenome Health
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Freenome Health
Freenome Health was founded in 2014.
Freenome Health is headquartered in United States.
Freenome Health is a funded company, having raised a total of $1.35B across 8 funding rounds to date. The company's 1st funding round was a Grant of $700K, raised on Jan 2014.
Freenome Health has 411 employees.
Freenome Health was founded in 2014 in the United States. A deep learning platform is offered for identifying circulating cancer-related markers in patient blood samples. Proprietary technology is utilized to detect cell-free DNA, immune cell fragments, and metabolic markers. Tumor types are classified through the platform, and treatment therapies for prostate, breast, colorectal, and lung cancers are supported in the health technology sector.
Freenome Health's top competitors include Geneoscopy, InterVenn and Miroculus.
Freenome Health offers Intelligent Screening Platform and Early Cancer Detection Tests.
Yes, Freenome Health is publicly traded on NASDAQ under the ticker symbol FRNM.
Freenome Health has made 1 acquisition, including Oncimmune.
Freenome Health has 65 investors. Key investors include Fidelity Investments, Verily, Kaiser Permanente, Exact Sciences, and Intermountain Healthcare.
The valuation of Freenome Health is $1.1B as of Jul 2026.
Freenome Health operates through Freenome Holdings, Inc..